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Abstract 
Tuberculosis (TB) is a global health burden, and a major cause of mortality and morbidity in West Africa. Here, we select key 
conserved pathogen epitopes of proven immunogenicity to form a potential TB epitope ensemble vaccine. We compared two vaccine 
formulations:  one comprising class I epitopes from the 13 most prevalent class I epitope-bearing antigens and class II epitopes 
deriving from the 20 most prevalent class II epitope-bearing antigens and another consisting of epitopes derived solely from 5 antigens 
identified as the most immunogenic by VaxiJen. In the prevalence analysis, 279 class I and 561 class II epitopes were collected and a 
subset selected using our published methodology, yielding 32 conserved epitopes. Combining 9 conserved epitopes gave a putative 
vaccine with predicted population coverage (PPC) over 95%. This consists of ISSGVFLLK, AVAGAAILV, WYYQSGLSI, YQSGLSIVM, 
MPVGGQSSF, QSSFYSDWY, WDINTPAFEWYYQSGLSIVM, DAPLITNPGGLLEQAVAVEE and NQAVTPAARALPLTSLTSAA. 5 
immunogenic antigens VaxiJen-identified yielded 187 epitopes, which we again analyzed using published protocol. This identified 11 
conserved epitopes. From this set the highest PPC value (<85%) was obtained by combining: GQQYQAMSAQAAAFH, 
DDIKATYDKGILTVSVAVSE and AVAGAAILV. We conclude that prioritizing epitope selection using predicted immunogenicity 
alone is likely to be unduly restrictive and is currently not an optimal or advisable strategy in the design of epitope ensemble vaccines.  
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Background: 
Mycobacterium Tuberculosis (TB) is a global health burden with 
an estimated 2015 death toll of 1.8 million, with 10.5 million new 
TB cases [1]. TB most commonly presents as a pulmonary disease 
transmitted via droplet inhalation resulting in symptoms 
including persistent cough, fever, and night sweats [2]. Some 
individuals can clear the disease, others will be asymptomatic 
with latent TB, and a proportion will suffer active TB. The slow 
rate of TB growth, combined with its complex pathogenesis and 
ability to lay dormant, poses as a major challenge to developing 
effective treatments. Vaccine development currently remains a 
priority, especially in developing countries where it is endemic, 
such as Africa, India, and Indonesia [3]. 
 
The immune response against TB predominantly involves T cell 
mediated immunity, specifically CD4+ and CD8+ T cells, which 
bind to complexes of class I or class II MHC bound to specific 
epitopes. Once activated, both CD4+ and CD8+ cells secrete 
cytokines inducing an immune response. CD8+ T cells also 
mediate cytotoxicity and the lysis of infected cells.  
 
The Bacillus Calmette-Guérin (BCG) anti-TB vaccine has been 
used for disease prophylaxis and control of TB progression for 
over 80 years. BCG is an attenuated form of mycobacterium bovis 
and is currently the only anti-TB vaccine in use worldwide. 
However, BCG has a well-attested variable efficacy (0-80%) in 
adult populations presenting with pulmonary TB [4], limiting its 
ability to prevent TB transmission. Thus the need for alternatives 
is clear. 
 
Several live vaccines are currently in development against TB 
including recombinant BCG VPM1002 and MTBVAC [5]. A key 
issue with live vaccines is their capacity to revert to a pathogenic 
form. This is a danger for immunocompromised individuals. 
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Viral vector-based vaccines include that based on the Ankara 
virus (MVA), modified to express TB antigen 85A, and an 
adenovirus expressing the mycobacterial antigens 85A, 85B and 
TB10.4, known as Crucell-Ad35/AERAS-402 vaccine [6]. 
Problems include the reduced efficacy of any resulting immunity 
due to previous exposure to the vector. There are several subunit 
vaccines being developed including the H1 vaccine, which 
combines 85B and ESAT-6 antigens, H4 vaccine which combines 
antigens 85B and TB10.4, and M72 which combines antigens 39A 
and 32A. The inability of subunit vaccines to induce long-term 
immunity necessitates multiple administrations or the inclusion 
of adjuvants. 
 
Here, we seek to identify pathogen epitopes able of form an 
epitope ensemble vaccine against TB. The complete genome 
sequence of Mycobacterium Tuberculosis H37Rv strain, 
comprising over 4 million base pairs and approximately 4,000 
genes [7], has helped in the search of vaccines against TB. An 
ideal vaccine would include highly conserved immunogenic 
epitopes with wide population coverage. Our recent studies 
exemplify this approach against viruses: Hepatitis C [8] and 
influenza [9]. Here we extend such work by addressing 
Mycobacterium Tuberculosis, a much larger and more complex 
bacterial pathogen. Specifically, we compared a vaccine 
comprised of epitopes from the most prevalent epitope-bearing 
antigens with one comprising epitopes deriving solely from 
antigens identified as most immunogenic by VaxiJen [10,11]. 
 
Methodology: 
Vaccine Design:  
We applied an epitope ensemble vaccine design protocol already 
described [8,9] to TB. Epitopes were extracted from the Immune 
Epitope Database and analysis resource (IEDB; URL: 
http://www.iedb.org/). Search criteria: positive T cell assays, 
human host only. Full protein sequences of epitope-bearing 
antigens were extracted from NCBI (URL: 
https://www.ncbi.nlm.nih.gov/protein/) and searched using 
BLAST-P (URL: https://blast.ncbi.nlm.nih.gov/Blast.cgi) against 
the Protein Reference Sequences (Refseq_protein). To reduce bias, 
10 sequences with high coverage and low identity were used to 
generate multiple sequence alignments. Sequence variability of 
the resulting alignments was calculated using the Protein 
Variability Server (PVS; URL: http://imed.med.ucm.es/PVS/), 
with a minimum fragment length of 9 and a variability threshold 
of 0.5. Class I and Class II binding profiles were calculated using 
IEDB’s consensus method for class I (URL: 
http://tools.immuneepitope.org/mhci/) and class II (URL: 
http://tools.immuneepitope.org/mhcii/). Only epitopes with a 
predicted IC50 < 500nM were retained. Predicted population 
coverage (PPC) was calculated using the IEDB PPC tool 
(http://tools.iedb.org/tools/population/iedb_input) for two 
populations of interest: West Africa and the World. See Figure 1.  
 
Immunogenicity Prediction: 
TB Antigens were processed using VzxiJen (URL: 
http://www.ddgpharmfac.net/vaxijen/Vaxijen.html), which 
predicts immunogenicity scores, allowing classification of 
antigens as either an antigen capable of inducing protective 
immunity or as a non-antigen [10,11]. Bacteria were selected as 
the target organism, with the threshold set at 0.5. The five top 
scoring antigens for class I and class II were then processed as 
above. See Figure 1. 
 
 
 
Figure 1: Protocol of epitope selection.  
 
Discussion: 
Two sets of epitope-bearing antigens were collected. The first 
dataset comprised proteins with greater than 10 epitopes. There 
were 13 Class I epitope-bearing antigens (Ag85B (59 class I 
epitopes), Putative ATP-dependent 6-phosphofructokinase 
isozyme 2 (28 epitopes), Alanine and proline-rich secreted 
protein Apa (26), Probable membrane protein Rv1733c (26), 
ESAT-6-like protein EsxB (23), ESAT-6-like protein EsxH (19), 
Low molecular weight T-cell antigen (17), 6 kDa early secretory 
antigenic target (16), Lipoprotein LpqH (14), PPE68 (14), Ag85A 
(13), Alpha-crystallin (13), MPT64 (11)) and 20 class II-bearing 
antigens (Ag85B (55 class II epitopes), 6 kDa early secretory 
antigenic target (55 epitopes), ESAT-6-like protein EsxB (45), 60 
kDa chaperonin 2 (42), Uncharacterized PPE family protein 
PPE19 (36), Ag85A (34), Putative ATP-dependent 6-
phosphofructokinase isozyme 2 (32), Alanine and proline-rich 
secreted protein Apa (30), Phosphate-binding protein PstS 1 (29), 
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Uncharacterized PPE family immunogenic protein PPE68 (27), 
MPT64 (24), Alpha-crystallin (22), Lipoprotein LpqH (21), 
Probable membrane protein Rv1733c (21), MPT70 ( 19), 10 kDa 
chaperonin (18), MPT83 (15), Putative phthiocerol 
dimycocerosate transporter LppX (12), ESAT-6-like protein EsxH 
(12), MPT63 (12).  
 
PVS identified conserved epitopes. From the 13 class I epitope-
bearing antigens, only 9 had conserved epitopes. Overall, 22 
conserved epitopes were found. The greatest number of epitopes 
was collected from diacylglycerol acyltransferase Ag85B (11), 
followed by lipoprotein LpqH (3), diacylglycerol acyltransferase 
Ag85A (2), alanine and proline-rich secreted protein Apa (2), 
PPE68 (1), ATP-PFK 2 (1) and alpha-crystallin (1). From the 20 
class I epitope-bearing antigens, only 5 had a total of 11 
conserved epitopes: ATP-PFK 2 (1), alanine and proline-rich 
secreted protein Apa (1), lipoprotein LpqH (1), diacylglycerol 
acyltransferase Ag85B (3), PPE19 (5). 
 
The second dataset comprised antigens with 3 or more epitopes 
for analysis using VAXIJEN. For class I, 22 antigens were 
identified. Antigens with the top 5 immunogenicity scores were 
identified: Lipoprotein LpqH (14 epitopes; score: 1.1666), 
Isoniazid-induced protein (3; 0.8784), ESAT-6-like protein EsxB 
(23, 0.8095), Alpha-crystallin (13; 0.8067), PPE68 (14; 0.6434). For 
class II, 61 antigens were identified. Antigens with the top 5 
immunogenicity scores were identified: PE_PGRS14 (3 epitopes; 
score: 1.9588), Lipoprotein LpqH (21; 1.1666), ESAT-6-like protein 
EsxB (45; 0.8095), Alpha-crystallin (22; 0.8067); PstS 1 (29; 0.7270). 
PVS identified conserved epitopes: for class I only 4 antigens had 
conserved epitopes, returning a total of 6 epitopes, and for class II 
only 3 of the 5 antigens had conserved epitopes, returning a total 
of 5 epitopes.  
 
For both VaxiJen and non-VaxiJen analysis, combinations of 
epitopes were assessed for population coverage. For the high-
prevalence set, non-VaxiJen analysis, the highest PPC value 
found was 98.75 (global) and 95.60 (West Africa). For the VaxiJen 
analysis, the highest PPC value found was 83.79 (global) and 
68.62 (West Africa). See Table 1. 
 
Table 1: Comparison of Vaccines in terms of Predicted Population Coverage  
 
 
EPITOPE COMBINATION 
 
OVERAL HLA BINDING PROFILE 
Predicted 
Population 
Coverage 
 WORLD (%) 
Predicted 
Population 
Coverage 
WEST 
AFRICA (%) 
Prevalence Analysis 
 
ISSGVFLLK, AVAGAAILV, 
WYYQSGLSI, YQSGLSIVM, 
MPVGGQSSF, QSSFYSDWY, 
DAPLITNPGGLLEQAVAVEE 
NQAVTPAARALPLTSLTSAA, 
GGLQHISSGVFLLKASVREL 
A*30:01, A*31:01, A*11:01, A*03:01, A*68:01, A*02:06, A*68:02, A*02:03, 
A*02:01, A*23:01, A*24:02, B*15:01, B*35:01, B*40:01, B*53:01, B*07:02, 
A*01:01, A*30:02, DRB1*01:01, DQA1*01:02/DBQ1*06:02, DRB1*13:02, 
DQA1*05:01/DQB1*03:01, DQA1*04:01/DQB1*04:02, 
DQA1*03:01/DQB1*03:02, DRB4*01:01, DRB1*09:01, DRB1*04:01, 
DRB1*08:01, DRB4*01:01, DPA1*01/DPB1*04:01, 
DPA1*01:03/DPB1*02:01, DPA1*02:01/DPB1*01:01, 
DPA1*03:01/DPB1*04:02, DRB1*04:05, DRB1*07:01, DRB1*08:02, 
DRB1*11:01, DRB1*15:01, DRB5*01:01  
 
 
 
98.79 
 
 
95.60 
VaxiJen Analysis 
 
GQQYQAMSAQAAAFH, 
DDIKATYDKGILTVSVAVSE, 
AVAGAAILV 
DQA1*01:02/DQB1*06:02, DQA1*04:01/DQB1*04:02, 
DQA1*05:01/DQB1*03:01, DRB1*01:01, DRB1*04:01, DRB1*04:05, 
DRB1*09:01, DRB1*11:01, DRB1*15:01, DRB4*01:01, DRB5*01:01, 
DRB1*01:01, DRB1*04:05, DRB1*07:01, DRB1*08:02, DRB1*13:02, 
DRB1*09:01, A*02:06, A*68:02, A*02:03, A*02:01 
 
 
 
83.29 
 
 
68. 62 
 
Compared to the unrestricted analysis, results from VaxiJen 
ranking were disappointing. Due to the small number of 
conserved epitopes identified, limited combinations could be 
undertaken. The conserved epitopes from VAXIJEN have similar 
HLA binding profiles. For class I, A*02:06, A*02:01 and A*02:03 
were the most common restrictions seen. The limited variation in 
binding profiles contributed to the low PPC values seen. The 
highest combined PPC values for both subsets contained the class 
I conserved epitope AVAGAAILV, derived from lipoprotein 
LpqH, consistent with the epitope being highly immunogenic 
and promiscuous. 
 
 
 
Conclusion: 
In this vaccine design exercise, we sought to limit selection to 
epitopes from major highly immunogenic antigens. Such 
constrained selection should concentrate the immune response 
on antigens more likely repeatedly to evoke strong responses in 
vivo. As an alternative to using all experimentally verified 
epitopes available, we used VaxiJen - the first and, ostensibly, the 
only on-line server for whole protein immunogenicity prediction 
- to rank antigens in terms of potential efficacy. However, 
prioritizing antigens using VaxiJen did not prove effective. This 
identifies a shortcoming of this method, due in no small part to 
the dearth of adequate training data. This is something we will 
seek to rectify in due course. Prevalence analysis, however, 
allowed for the total pool of available epitopes to be tractable yet 
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large enough to generate an optimal hypothetical vaccine 
candidate. Epitope combinations derived through epitope-
prevalence analysis had sufficiently high population coverage to 
generate effective potential universal epitope ensemble vaccines. 
However, due to the low immunogenicity traditionally 
associated with peptide vaccines, such candidates are likely to 
require the addition of adjuvants. Overall, we have shown how 
computational approaches can identify a potential ensemble 
vaccine against a major bacterial pathogen by selecting epitopes 
of known, validated immunogenicity with broad population 
coverage. These will now need experimental validation to 
determine the efficacy and safety of the vaccine in live subjects.  
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